Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon α-2a (40KD) plus ribavirin

Liver International

Volumn 28, Issue 1, 2008, Pages 61-71

  Snoeck, Eric ^a   Hadziyannis, Stephanos J ^b   Puoti, Claudio ^c   Swain, Mark G ^d   Berg, Thomas ^e   Marcellin, Patrick ^f   Zarski, Jean Pierre ^g   Jorga, Karin ^h,i   Zeuzem, Stefan ⁱ  

^a Exprimo NV   (Belgium)

^b HENRY DUNANT HOSPITAL   (Greece)

^c Marino Hospital Rome   (Italy)

^d UNIVERSITY OF CALGARY   (Canada)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL MICHALLON   (France)

^h Saarland University Hospital ^*

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Model; Peginterferon 2a; Simulation; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; SIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

ALANINE TRANSAMINASE; ANEMIA; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MODELS, THEORETICAL; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 37449031393     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01603.x     Document Type: Article

References (20)

1. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 -June 10-12, 2002. Hepatology 2002; 36: S3-20.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-7.
6. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-9.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
9. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
10. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
11. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
12. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
13. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications. AAPS J 2005; 7: E503-12.
14. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005; 7: E544-59.
15. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005; 32: 185-97.
16. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68: 677-8.
17. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006; 62: 699-709.
18. F.Hoffmann-La Roche Inc. COPEGUS (ribavirin USP) prescribing information. 2005. Available online at http://www.rocheusa.com/products/ copegus/pi.PDF. Accessed on 15 September 2005.
19. Jacobson IM, Brown RS, Freilich B, et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, A US community based trial. Hepatology 2005; 42 (Suppl. 1): 749A.
20. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.